ANI Pharmaceuticals
Open
$79.33
Prev. Close
$79.33
High
$79.33
Low
$79.29
Market Snapshot
$1.75B
22.7
-1.12
$614.38M
970
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
emptyResult
ANI Pharmaceuticals, Inc. is a bio-pharmaceutical company, which engages in the development, manufacture, and marketing of branded and generic prescription pharmaceuticals. The company is headquartered in Baudette, Minnesota and currently employs 970 full-time employees. The company went IPO on 2000-05-04. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.
Recently from Cashu
ANI Pharmaceuticals Expands Portfolio with Isosorbide Mononitrate and ILUVIEN Clinical Trial Results
ANI Pharmaceuticals has made significant strides in expanding its product offerings in the pharmaceutical market. The recent launch of Isosorbide Mononitrate Tablets marks a notable addition to its gr…
ANI Pharmaceuticals: Executive Stock Option Exercise Signals Commitment to Growth Strategy
ANI Pharmaceuticals’ Strategic Executive Actions Highlight Commitment to Growth In a recent SEC filing dated March 5, ANI Pharmaceuticals' Senior Vice President and Chief Financial Officer, Caryn Care…
Carey’s Stock Option Exercise Highlights Commitment to ANI Pharmaceuticals’ Long-Term Growth Strategy
Executive Actions Reflect Commitment to ANI Pharmaceuticals’ Future Strategy ANI Pharmaceuticals’ recent SEC filing highlights a significant transaction executed by Senior Vice President and Chief Fin…
Insider Buying by ANI Pharmaceuticals Executives Signals Confidence in Future Growth
### Ground-Level Confidence: ANI Pharmaceuticals' Executives Make Insider Purchases On March 2, 2023, a series of insider purchases by senior executives at ANI Pharmaceuticals (NASDAQ:ANIP) raised eye…